BCM
SPRB

Bridgeway Capital Management’s Spruce Biosciences SPRB Stock Holding History

Bridgeway Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-465
Closed -$14.7K – 1263
2024
Q4 		$14.7K Sell
465
-68
-13% -$2.49K ﹤0.01% 1188
2024
Q3 		$19K Sell
533
-600
-53% -$22K ﹤0.01% 1245
2024
Q2 		$44K Hold
1,133
– – ﹤0.01% 1231
2024
Q1 		$66.8K Hold
1,133
– – ﹤0.01% 1248
2023
Q4 		$249K Hold
1,133
– – 0.01% 1092
2023
Q3 		$192K Hold
1,133
– – ﹤0.01% 1109
2023
Q2 		$183K Hold
1,133
– – ﹤0.01% 1154
2023
Q1 		$188K Buy
1,133
+333
+42% +$61.8K 0.01% 1117
2022
Q4 		$66K Hold
800
– – ﹤0.01% 1273
2022
Q3 		$82K Hold
800
– – ﹤0.01% 1307
2022
Q2 		$104K Sell
800
-2,484
-76% -$318K ﹤0.01% 1216
2022
Q1 		$495K Buy
3,284
+486
+17% +$90.4K 0.01% 940
2021
Q4 		$936K Buy
+2,798
New +$833K 0.02% 803

Other funds holding SPRB

CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bridgeway Capital Management's SPRB Position: Q1 2025 in Review

Bridgeway Capital Management sold out of Spruce Biosciences (SPRB) in Q1 2025, closing a stake of 465 shares — an estimated $14.7K sold.

Bridgeway Capital Management first reported a position in SPRB in Q4 2021 and held it in 13 quarters. The position peaked at $936K in Q4 2021. 31 funds tracked by Wall St. Rank hold SPRB as of Q1 2025.

  • Bridgeway Capital Management reported no remaining Spruce Biosciences position as of Q1 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 465 Spruce Biosciences shares in Q1 2025, an estimated $14.7K.
  • Bridgeway Capital Management first reported a position in Spruce Biosciences in Q4 2021 and held it in 13 quarters.
  • Bridgeway Capital Management's Spruce Biosciences position peaked at $936K in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2025.

Based on Bridgeway Capital Management's 13F filing for Q1 2025, filed 15 May 2025.